By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising ...

Popular weight-loss drugs are meant to be lifelong medications treating a disease, not lifestyle fixes.

Novo Nordisk (NVO) stock is in focus as the company's advertising expenditure for its GLP-1s, Wegovy and Ozempic, exceeds that for Lilly's (LLY) rivals. Read more here.

Monthly injections, once-daily pills, and even lifelong gene therapies could soon become options for people looking to lose ...

The 23-time Grand Slam champion tells PEOPLE that she feels better than ever since dropping 34 lbs. with a GLP-1 ...

Serena Williams has appeared in several Super Bowl commercials, but never one quite like this. In a new spot from ...

By Amina Niasse NEW YORK, Jan 28 (Reuters) - Telehealth company Ro has had an influx of new customers seeking the newly ...

Ro is making its Super Bowl debut, enlisting Williams to challenge misconceptions about GLP-1 use.

At a high level these drugs mimic glucagon-like peptide-1, or GLP-1, a hormone our bodies naturally produce in the gut. When ...

The Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the ...

As layoffs pile up, workers are feeling increasingly anxious about the job market. Economists have said businesses are in a "no-hire, no-fire" standstill as hiring stalls overall. But a growing ...

“I counsel every patient on the importance of protein intake when they start this. When most people go into a diet program ...